NCT06395038View on ClinicalTrials.gov

IL-2 Plus Abatacept in FTD

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Frontotemporal Degeneration
Interventions
DRUG

Abatacept plus Aldesleukin

CTLA4IgG plus Low dose Interleukin-2 (Aldesleukin) administration to modify immune responses

Trial Locations (1)

77030

RECRUITING

Houston Methodist Research Institute, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER